Tulpule Lab
banner
tulpulelab.bsky.social
Tulpule Lab
@tulpulelab.bsky.social
Pediatric oncologist and Physician-Scientist at MSKCC. Receptor tyrosine kinase (RTK) fusions and condensates in cancer. DNA repair. Pediatric sarcomas. https://www.mskcc.org/research-areas/labs/asmin-tulpule
Thanks Anton! Important question - my view is that fusion-induced replication stress, like PGBD5 expression, likely contribute to the ATR inhibitor responsiveness of ES (mentioned in Discussion), but whether/how RS impairs the physiologic DNA repair response is less clear to me. Curious your view?
November 26, 2024 at 2:57 PM
Interested in pediatric cancer and DNA repair? We are recruiting PhD students and postdocs, so please reach out and come join us in NYC. #MSKKids
November 25, 2024 at 4:57 PM
We would love to hear feedback, opportunities for new directions and collaborations. This is the work of many at UCSF and MSKCancerCenter, but led by 2 super star postdocs
Shruti Menon and Daniel Gracilla.
November 25, 2024 at 4:57 PM
3. Cell-line and PDX testing of the ATR inhibitor elimusertib as a synthetic lethal therapeutic strategy to target ATM defects across the class of FET rearranged tumors.
November 25, 2024 at 4:56 PM
2. New mechanistic studies of the interaction/competition between EWSR1-FLI1 (the Ewing fusion) and native FET proteins (i.e., EWSR1) at DNA double-strand breaks.
November 25, 2024 at 4:55 PM
1. Direct comparison of EWSR1-FLI1’s suppressive effects on ATM activation/signaling with loss of canonical ATM activators to benchmark the effect size and demonstrate the biological significance of the (partial) ATM defects we report here.
November 25, 2024 at 4:55 PM
Great list, would love to be added!
November 24, 2024 at 8:49 PM